PT2552955T - Anticorpos com afinidade modificada para fcrn que promovem a depuração de antigénios - Google Patents

Anticorpos com afinidade modificada para fcrn que promovem a depuração de antigénios

Info

Publication number
PT2552955T
PT2552955T PT117148601T PT11714860T PT2552955T PT 2552955 T PT2552955 T PT 2552955T PT 117148601 T PT117148601 T PT 117148601T PT 11714860 T PT11714860 T PT 11714860T PT 2552955 T PT2552955 T PT 2552955T
Authority
PT
Portugal
Prior art keywords
fcrn
antibodies
antigen purification
promote antigen
modified affinity
Prior art date
Application number
PT117148601T
Other languages
English (en)
Portuguese (pt)
Inventor
Igawa Tomoyuki
Ishii Shinya
Maeda Atsuhiko
Nakai Takashi
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44260244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2552955(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of PT2552955T publication Critical patent/PT2552955T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials For Photolithography (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Slot Machines And Peripheral Devices (AREA)
  • Medicinal Preparation (AREA)
PT117148601T 2010-03-30 2011-03-30 Anticorpos com afinidade modificada para fcrn que promovem a depuração de antigénios PT2552955T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010079667 2010-03-30
JP2010250830 2010-11-09

Publications (1)

Publication Number Publication Date
PT2552955T true PT2552955T (pt) 2017-07-12

Family

ID=44260244

Family Applications (2)

Application Number Title Priority Date Filing Date
PT171545767T PT3181581T (pt) 2010-03-30 2011-03-30 Anticorpos com afinidade modificada para fcrn que promovem a depuração de antigénios
PT117148601T PT2552955T (pt) 2010-03-30 2011-03-30 Anticorpos com afinidade modificada para fcrn que promovem a depuração de antigénios

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT171545767T PT3181581T (pt) 2010-03-30 2011-03-30 Anticorpos com afinidade modificada para fcrn que promovem a depuração de antigénios

Country Status (21)

Country Link
US (6) US20130131319A1 (enExample)
EP (4) EP3702368B1 (enExample)
JP (8) JP5415624B2 (enExample)
KR (6) KR101831464B1 (enExample)
CN (2) CN113307868A (enExample)
AU (1) AU2011233390B2 (enExample)
BR (1) BR112012024710B1 (enExample)
CA (1) CA2794860C (enExample)
DK (1) DK2552955T3 (enExample)
ES (3) ES2995193T3 (enExample)
HR (3) HRP20241779T1 (enExample)
HU (3) HUE069966T2 (enExample)
LT (1) LT2552955T (enExample)
MX (1) MX2012011338A (enExample)
PL (3) PL3702368T3 (enExample)
PT (2) PT3181581T (enExample)
RU (1) RU2745989C9 (enExample)
SG (2) SG10201703798YA (enExample)
SI (2) SI3181581T1 (enExample)
TW (2) TWI667346B (enExample)
WO (1) WO2011122011A2 (enExample)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2006381B1 (en) * 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
CL2008002886A1 (es) 2007-09-26 2009-12-04 Chugai Pharmaceutical Co Ltd Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende.
CA2700701C (en) 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
NZ717429A (en) 2008-04-11 2018-07-27 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
DK2698431T3 (da) * 2011-03-30 2020-11-30 Chugai Pharmaceutical Co Ltd Opretholdelse af antigen-bindende molekyler i blodplasma og fremgangsmåde til modifikation af immunogenicitet
TWI687441B (zh) 2011-06-30 2020-03-11 中外製藥股份有限公司 異源二聚化多胜肽
US20150050269A1 (en) * 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
SG11201401101XA (en) * 2011-09-30 2014-08-28 Chugai Pharmaceutical Co Ltd Antigen-binding molecule for promoting loss of antigens
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
TW201945034A (zh) 2011-09-30 2019-12-01 日商中外製藥股份有限公司 包含依離子濃度之條件對抗原之結合活性會改變之抗原結合分域、及於pH中性之條件下對FcRn有結合活性之FcRn結合分域、且誘導對標的抗原的免疫反應之抗原結合分子
EP2787081A4 (en) * 2011-11-30 2015-10-07 Chugai Pharmaceutical Co Ltd PHARMACEUTICAL CARRIER IN CELLS FOR THE FORMATION OF AN IMMUNOMOPLEX
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
SG11201404751UA (en) 2012-02-09 2014-09-26 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
CN104125852B9 (zh) 2012-02-15 2017-05-17 弗·哈夫曼-拉罗切有限公司 基于Fc‑受体的亲和色谱
TWI682939B (zh) * 2012-02-24 2020-01-21 日商中外製藥股份有限公司 經ＦｃγＲＩＩＢ促進抗原消失之抗原結合分子
NZ730271A (en) 2012-03-16 2022-09-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
ES2665793T3 (es) * 2012-03-16 2018-04-27 Regeneron Pharmaceuticals, Inc. Anticuerpos de cadena ligera modificada mediante ingeniería genética con histidina y roedores modificados genéticamente para la generación de los mismos
CN104302170B (zh) * 2012-03-16 2016-09-28 瑞泽恩制药公司 生产具有ph依赖性结合特性的抗原结合蛋白的小鼠
RU2014147741A (ru) * 2012-04-27 2016-06-20 Байоатла Ллк. Модифицированные области антител и их применение
CN107759686A (zh) 2012-05-30 2018-03-06 中外制药株式会社 靶组织特异性抗原结合分子
ES2856272T3 (es) * 2012-05-30 2021-09-27 Chugai Pharmaceutical Co Ltd Molécula de unión a antígenos para eliminar antígenos agregados
EP3721900A1 (en) 2012-08-24 2020-10-14 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc region variant
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
KR102249779B1 (ko) 2012-12-27 2021-05-07 추가이 세이야쿠 가부시키가이샤 헤테로이량화 폴리펩티드
GB201302878D0 (en) * 2013-02-19 2013-04-03 Argen X Bv Modified igG molecules
KR102318483B1 (ko) 2013-04-02 2021-10-27 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
KR102266819B1 (ko) 2013-04-29 2021-06-18 에프. 호프만-라 로슈 아게 Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법
ES2746136T3 (es) 2013-04-29 2020-03-04 Hoffmann La Roche Anticuerpos modificados de unión a FcRn humano y procedimientos de uso
MX382731B (es) 2013-09-27 2025-03-13 Chugai Pharmaceutical Co Ltd Metodo para producir heteromultimeros de polipeptidos.
BR112016006502A2 (pt) 2013-09-30 2017-09-19 Chugai Pharmaceutical Co Ltd Método para a produção de molécula de ligação de antígeno usando-se fago auxiliar modificado
EP3070168B1 (en) 2013-11-11 2024-07-31 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
KR20240134226A (ko) 2013-12-04 2024-09-06 추가이 세이야쿠 가부시키가이샤 화합물의 농도에 따라 항원 결합능이 변화되는 항원 결합 분자 및 그의 라이브러리
RU2698969C2 (ru) 2014-01-15 2019-09-02 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с улучшенной способностью связываться с белком а
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
KR20160134687A (ko) 2014-03-21 2016-11-23 에프. 호프만-라 로슈 아게 항체의 생체내 반감기의 시험관내 예측방법
JP6832709B2 (ja) 2014-05-16 2021-02-24 メディミューン，エルエルシー 新生児Ｆｃ受容体結合が改変されて治療および診断特性が強化された分子
WO2015189249A1 (en) * 2014-06-12 2015-12-17 F. Hoffmann-La Roche Ag Method for selecting antibodies with modified fcrn interaction
FR3024453B1 (fr) * 2014-08-01 2018-06-29 Lab Francais Du Fractionnement Procede de production de variants ayant un fc presentant une sialylation amelioree
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
BR112017006591A2 (pt) * 2014-11-06 2018-01-16 Hoffmann La Roche polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico
BR112017006178A2 (pt) * 2014-11-06 2018-05-02 F. Hoffmann-La Roche Ag região fc, anticorpos, formulação farmacêutica e usos dos anticorpos
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
WO2016076345A1 (ja) 2014-11-11 2016-05-19 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子のライブラリ
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
TWI617580B (zh) 2014-12-19 2018-03-11 中外製藥股份有限公司 抗ｃ５抗體及使用方法
WO2016117346A1 (en) 2015-01-22 2016-07-28 Chugai Seiyaku Kabushiki Kaisha A combination of two or more anti-c5 antibodies and methods of use
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
EP4269440A3 (en) 2015-02-27 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
PT3922645T (pt) 2015-09-15 2025-05-29 Scholar Rock Inc ¿anticorpos anti-pró-miostatina/miostatina latente e suas utilizações
MX2018003005A (es) 2015-09-18 2018-04-11 Chugai Pharmaceutical Co Ltd Anticuerpos que se unen a interleucina 8 (il-8) y sus usos.
TWI605057B (zh) 2015-12-18 2017-11-11 中外製藥股份有限公司 抗肌抑素抗體、含變異ｆｃ區之多肽及使用方法
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
JP2019504064A (ja) 2016-01-08 2019-02-14 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型ミオスタチン抗体およびその使用方法
CN109475630A (zh) 2016-05-27 2019-03-15 瑞颂医药公司 治疗难治性全身型重症肌无力的方法
CN109641957B (zh) * 2016-06-06 2022-10-04 希望之城 Baff-r抗体及其用途
EP4374922A3 (en) 2016-06-14 2024-08-28 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof
TWI760396B (zh) 2016-06-17 2022-04-11 日商中外製藥股份有限公司 抗肌抑素抗體及使用方法
IL315729A (en) 2016-08-02 2024-11-01 Visterra Inc Fc region containing polypeptides and uses thereof
TW202300168A (zh) 2016-08-05 2023-01-01 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
US10669344B2 (en) 2016-08-12 2020-06-02 Janssen Biotech, Inc. Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
SG11201903302UA (en) 2016-10-14 2019-05-30 Xencor Inc Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
DK3565592T5 (da) 2017-01-06 2024-09-02 Scholar Rock Inc Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering
EP3569615A4 (en) * 2017-01-13 2020-07-29 Hanx Biopharmaceutics, Inc PROCESS FOR IMPROVING THE BINDING AFFINITY OF AN IGG ANTIBODY TOWARDS FCRN AND PROLONGING THE SERIC HALF-LIFE OF THE latter
JP7191833B2 (ja) 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用
KR101949891B1 (ko) 2017-01-31 2019-02-19 추가이 세이야쿠 가부시키가이샤 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
EP3580233A1 (en) * 2017-02-10 2019-12-18 Genmab B.V. Polypeptide variants and uses thereof
PL3583120T3 (pl) 2017-02-17 2023-01-09 Denali Therapeutics Inc. Konstruowane polipeptydy wiążące receptory transferyny
CA3120566C (en) * 2017-04-07 2023-12-12 Kookmin University Industry Academy Cooperation Foundation Antibody fc variants for increased blood half-life
JP2020517242A (ja) 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー 抗ＡｐｏＣ３抗体およびその使用方法
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
JP7710827B2 (ja) * 2017-06-05 2025-07-22 ヤンセン バイオテツク，インコーポレーテツド 非対称なｃｈ２－ｃｈ３領域の変異を有する、操作された多重特異性抗体及び他の多量体タンパク質
US11084863B2 (en) 2017-06-30 2021-08-10 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
PT3658184T (pt) 2017-07-27 2023-11-29 Alexion Pharma Inc Formulações de anticorpo anti-c5 de elevada concentração
CN111032688A (zh) 2017-08-11 2020-04-17 研究发展基金会 用于延长的血清半衰期的工程化抗体fc变体
CN111757730A (zh) 2017-10-06 2020-10-09 普罗塞纳生物科学有限公司 检测甲状腺素运载蛋白的方法
WO2019071205A1 (en) 2017-10-06 2019-04-11 Prothena Biosciences Limited ANTI-TRANSTHYRETIN ANTIBODY
WO2019078357A1 (ja) * 2017-10-20 2019-04-25 中外製薬株式会社 細胞への分子の取り込みを測定する方法
BR112020008182A2 (pt) 2017-10-26 2020-10-27 Alexion Pharmaceuticals, Inc. dosagem e administração de anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna (hpn) e síndrome hemolítica urêmica atípica (shua)
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
MA50516A (fr) 2017-10-31 2020-09-09 Staten Biotechnology B V Anticorps anti-apoc3 et leurs procédés d'utilisation
CN111556895B (zh) 2017-11-14 2024-09-13 中外制药株式会社 抗-c1s抗体及使用方法
BR112020010483A2 (pt) 2017-11-29 2020-10-20 Prothena Biosciences Limited formulação liofilizada de um anticorpo monoclonal contra transtirretina
US11952422B2 (en) 2017-12-05 2024-04-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
SG11202004662RA (en) 2017-12-13 2020-06-29 Regeneron Pharma Anti-c5 antibody combinations and uses thereof
JP2021511812A (ja) * 2018-02-02 2021-05-13 オンコイミューン， インコーポレイテッド がん治療のためのより安全でより効果的な抗ｃｔｌａ４抗体を選択及び設計する方法
CN111699195A (zh) * 2018-02-02 2020-09-22 肿瘤免疫股份有限公司 具有改善的免疫治疗效果但减轻的不良作用的突变体抗ctla-4抗体
KR20200132938A (ko) 2018-03-15 2020-11-25 추가이 세이야쿠 가부시키가이샤 지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법
CN116420679B (zh) * 2018-03-26 2025-10-03 瑞泽恩制药公司 用于测试治疗剂的人源化啮齿动物
CA3096222A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
MA52248A (fr) * 2018-04-13 2021-02-17 Chugai Pharmaceutical Co Ltd Anticorps dirigés contre un composant du complément et procédés d'utilisation
JP2021520829A (ja) 2018-04-18 2021-08-26 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
CN112867734A (zh) 2018-04-18 2021-05-28 Xencor股份有限公司 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
IL278090B2 (en) 2018-04-18 2024-07-01 Xencor Inc Il-15/il-15rα heterodimeric fc fusion proteins and uses thereof
EA202092306A1 (ru) 2018-05-14 2021-02-19 Онкоиммьюн, Инк. Анти-cd24 композиции и их применения
JP7520725B2 (ja) 2018-05-31 2024-07-23 アレクシオン ファーマシューティカルズ， インコーポレイテッド 小児患者における発作性夜間ヘモグロビン尿症（ｐｎｈ）の治療のための抗ｃ５抗体の用量および投与
US12460012B2 (en) 2018-06-04 2025-11-04 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients
GB201809341D0 (en) 2018-06-07 2018-07-25 Ucb Biopharma Sprl Multi-domain proteins with increased native state colloidal stability
CN112424358B (zh) 2018-06-26 2025-07-01 协和麒麟株式会社 与细胞粘附分子3结合的抗体
CN112424357B (zh) 2018-06-26 2024-12-24 协和麒麟株式会社 与硫酸软骨素蛋白聚糖5结合的抗体
EP3814373A1 (en) 2018-06-28 2021-05-05 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
SMT202400102T1 (it) 2018-07-19 2024-05-14 Regeneron Pharma Recettori chimerici dell’antigene con specificità per bcma e loro usi
US20210301004A1 (en) 2018-08-01 2021-09-30 Chugai Seiyaku Kabushiki Kaisha A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
SG10202106830VA (en) 2018-08-10 2021-08-30 Chugai Pharmaceutical Co Ltd Anti-cd137 antigen-binding molecule and utilization thereof
CA3116188A1 (en) 2018-10-12 2020-04-16 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
US12240893B2 (en) 2018-10-30 2025-03-04 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)
PE20211867A1 (es) * 2018-11-01 2021-09-21 Shandong New Time Pharmaceutical Co Ltd Anticuerpos biespecificos y su uso
CN113227131B (zh) 2018-12-20 2025-03-04 豪夫迈·罗氏有限公司 经修饰的抗体Fc及其使用方法
EP3897853A1 (en) 2018-12-20 2021-10-27 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
WO2020189748A1 (ja) 2019-03-19 2020-09-24 中外製薬株式会社 Ｍｔａ依存的に抗原に対する結合活性が変化する抗原結合ドメインを含む抗原結合分子及び当該抗原結合ドメイン取得用ライブラリ
AU2020273072A1 (en) 2019-04-10 2021-12-09 Chugai Seiyaku Kabushiki Kaisha Method for purifying Fc region-modified antibody
GB2589049C (en) 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
EP3957325A4 (en) * 2019-04-19 2023-01-04 Chugai Seiyaku Kabushiki Kaisha CHEMERA RECEPTOR RECOGNIZING AN ANTIBODY MODIFICATION SITE
US12473353B2 (en) 2019-05-15 2025-11-18 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule, a pharmaceutical composition, and a method
US20220298260A1 (en) * 2019-06-06 2022-09-22 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
AU2020287378A1 (en) * 2019-06-06 2022-02-03 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
MX2021015095A (es) * 2019-06-07 2022-03-22 Mythic Therapeutics Inc Construcciones de proteínas de unión a antígenos y usos de estos.
US20220288219A1 (en) * 2019-07-08 2022-09-15 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
WO2021022039A1 (en) * 2019-07-30 2021-02-04 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
EP4013785A4 (en) * 2019-08-12 2023-12-20 CSL Innovation Pty Ltd COMPLEMENT C2 BINDING PROTEINS AND THEIR USES
US11807687B2 (en) 2019-10-03 2023-11-07 Atyr Pharma, Inc. Therapeutic compositions comprising anti-NRP2 antibodies
AU2020357980A1 (en) * 2019-10-04 2022-05-26 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
US20220396618A1 (en) * 2019-10-31 2022-12-15 The Research Foundation For The State University Of Newyork Rage antibodies, fragments and uses thereof
CN114867532A (zh) 2019-12-18 2022-08-05 豪夫迈·罗氏有限公司 双特异性抗ccl2抗体
CA3162444C (en) 2019-12-27 2024-04-30 Hitoshi KATADA Anti-ctla-4 antibody and use thereof
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
JP7634545B2 (ja) * 2020-01-29 2025-02-21 コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション ｐＨ感応性ＦＣ変異体
TWI895351B (zh) 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
EP4133269A1 (en) * 2020-04-08 2023-02-15 F. Hoffmann-La Roche AG Large molecule unspecific clearance assay
US20230416371A1 (en) 2020-08-28 2023-12-28 Chugai Seiyaku Kabushiki Kaisha Heterodimer fc polypeptide
US11912781B2 (en) 2021-01-13 2024-02-27 Visterra, Inc. Humanized complement 5A receptor 1 antibodies and methods of use thereof
LT4288456T (lt) 2021-02-03 2024-12-27 Mythic Therapeutics, Inc. Antikūnai prieš met ir jų panaudojimas
CN117500829A (zh) 2021-06-18 2024-02-02 豪夫迈·罗氏有限公司 双特异性抗ccl2抗体
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
CN119838007A (zh) 2021-06-25 2025-04-18 中外制药株式会社 抗ctla-4抗体的用途
WO2022270611A1 (ja) 2021-06-25 2022-12-29 中外製薬株式会社 抗ｃｔｌａ－４抗体
CN115572331A (zh) * 2021-07-06 2023-01-06 联邦生物科技(珠海横琴)有限公司 一种具有增强FcRn受体结合的突变子
AU2022328727A1 (en) * 2021-08-20 2024-03-07 The Government Of The United States, As Represented By The Secretary Of The Army IgA MONOCLONAL ANTIBODIES FOR TREATING FLAVIVIRUS INFECTION
WO2024092031A1 (en) 2022-10-25 2024-05-02 Seismic Therapeutic, Inc. VARIANT IgG FC POLYPEPTIDES AND USES THEREOF
EP4638496A1 (en) 2022-12-22 2025-10-29 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation
CN120882427A (zh) * 2023-03-24 2025-10-31 派拉冈医疗公司 结合FcRn的Fc片段和使用方法
AR133427A1 (es) 2023-07-31 2025-09-24 Sanofi Sa Anticuerpos anti-gprc5d y composiciones
GB202319605D0 (en) 2023-12-20 2024-01-31 argenx BV Monovalent binding molecules and methods of use
CN120365429B (zh) * 2025-06-30 2025-09-05 上海交通大学医学院附属仁济医院 Cd70特异性纳米抗体、分子影像探针及其制备方法和应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPS63149900A (ja) 1986-12-15 1988-06-22 Toshiba Corp 半導体メモリ
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
DE69333823T2 (de) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
WO1995015393A1 (en) 1993-12-03 1995-06-08 Asahi Kasei Kogyo Kabushiki Kaisha Novel expression screening vector
JPH09506508A (ja) 1993-12-03 1997-06-30 メディカル リサーチ カウンシル 組換え結合タンパク質およびペプチド
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
AU701342B2 (en) 1994-07-13 1999-01-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
SK40599A3 (en) 1996-09-26 2000-06-12 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
US7417130B2 (en) 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
EP1331266B1 (en) 2000-10-06 2017-01-04 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
AU1325102A (en) 2000-10-16 2002-04-29 Phylos Inc Protein scaffolds for antibody mimics and other binding proteins
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2442801A1 (en) 2001-04-02 2002-10-10 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with gntiii
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20060141456A1 (en) 2002-06-12 2006-06-29 Cynthia Edwards Methods and compositions for milieu-dependent binding of a targeted agent to a target
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
WO2005047327A2 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
PT1706424E (pt) 2004-01-12 2009-10-01 Applied Molecular Evolution Variantes da região fc
DE102004032634A1 (de) 2004-07-06 2006-02-16 Sms Demag Ag Verfahren und Einrichtung zum Messen und Regeln der Planheit und/oder der Bandspannungen eines Edelstahlbandes oder einer Edelstahlfolie beim Kaltwalzen in einem Vielwalzengerüst, insbesondere in einem 20-Walzen-Sendizimir-Walzwerk
PL1776384T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
ZA200701715B (en) 2004-08-19 2008-07-30 Genentech Inc Polypeptide variants with altered effector function
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP2314618A3 (en) 2004-11-12 2011-10-19 Xencor Inc. Fc variants with altered binding to FcRn
US20090061485A1 (en) 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
MX2007008017A (es) 2004-12-31 2007-09-12 Genentech Inc Polipeptidos que se ligan a br3 y usos de los mismos.
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
MX2008014692A (es) 2006-05-19 2009-08-18 Alder Biopharmaceuticals Inc Metodo de cultivo para obtener una poblacion clonal de celulas b especificas de antigeno.
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
KR101616758B1 (ko) * 2007-12-26 2016-04-29 젠코어 인코포레이티드 ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체
JP5373823B2 (ja) * 2008-01-29 2013-12-18 アブリンクス エン．ヴェー． タンパク質及びポリペプチドを安定化する方法
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
NZ717429A (en) * 2008-04-11 2018-07-27 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CA2726845C (en) 2008-06-04 2017-09-26 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
JP5028372B2 (ja) 2008-09-26 2012-09-19 京セラドキュメントソリューションズ株式会社 画像処理装置、画像処理方法及び画像処理プログラム
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
CN110317272A (zh) * 2008-10-14 2019-10-11 霍夫曼-拉罗奇有限公司 免疫球蛋白变体及其用途
JP2010250827A (ja) 2009-04-16 2010-11-04 Accenture Global Services Gmbh タッチポイントをカスタマイズするシステム
LT2536745T (lt) * 2010-02-19 2016-09-26 Xencor, Inc. Nauji ctla4-ig imunoadhezinai
WO2011111007A2 (en) * 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
US10183994B2 (en) 2014-06-30 2019-01-22 Merck Patent Gmbh Anti-TNFα antibodies with pH-dependent antigen binding for improved target clearence

Also Published As

Publication number Publication date
CA2794860A1 (en) 2011-10-06
US20130131319A1 (en) 2013-05-23
KR20180019764A (ko) 2018-02-26
PL3702368T3 (pl) 2025-03-24
US20170226206A1 (en) 2017-08-10
JP5415624B2 (ja) 2014-02-12
US20170002066A1 (en) 2017-01-05
RU2745989C2 (ru) 2021-04-05
RU2012146098A (ru) 2014-05-10
JP6029252B2 (ja) 2016-11-24
KR20240094003A (ko) 2024-06-24
US20170002080A1 (en) 2017-01-05
JP2019178134A (ja) 2019-10-17
PL3181581T3 (pl) 2025-02-10
US20230220083A1 (en) 2023-07-13
WO2011122011A2 (en) 2011-10-06
JP5913243B2 (ja) 2016-04-27
EP2552955B1 (en) 2017-05-03
AU2011233390B2 (en) 2015-08-20
JP2014065708A (ja) 2014-04-17
HRP20241779T1 (hr) 2025-02-28
JP6518222B2 (ja) 2019-05-22
TWI667257B (zh) 2019-08-01
KR20130010002A (ko) 2013-01-24
SI3181581T1 (sl) 2025-02-28
JP2017036318A (ja) 2017-02-16
KR20210079407A (ko) 2021-06-29
EP3702368C0 (en) 2024-11-20
HUE033812T2 (en) 2018-01-29
LT2552955T (lt) 2017-07-25
WO2011122011A3 (en) 2012-01-05
SG184163A1 (en) 2012-10-30
BR112012024710B1 (pt) 2022-06-07
HRP20241623T1 (hr) 2025-02-14
JP2021091725A (ja) 2021-06-17
EP3702368A1 (en) 2020-09-02
JP2016145222A (ja) 2016-08-12
BR112012024710A2 (pt) 2021-04-27
KR20220157513A (ko) 2022-11-29
SG10201703798YA (en) 2017-06-29
AU2011233390A1 (en) 2012-11-08
US20160244526A1 (en) 2016-08-25
KR102269707B1 (ko) 2021-06-25
JP7186813B2 (ja) 2022-12-09
MX2012011338A (es) 2012-11-30
SI2552955T1 (sl) 2017-08-31
TW201700499A (zh) 2017-01-01
KR20190047111A (ko) 2019-05-07
EP3181581A1 (en) 2017-06-21
EP3702368B1 (en) 2024-11-20
CN102918057B (zh) 2021-06-01
JP2023022203A (ja) 2023-02-14
PL2552955T3 (pl) 2017-12-29
TW201202419A (en) 2012-01-16
KR101831464B1 (ko) 2018-02-22
CN113307868A (zh) 2021-08-27
JP2025081443A (ja) 2025-05-27
ES2995193T3 (en) 2025-02-07
CA2794860C (en) 2022-05-17
DK2552955T3 (en) 2017-08-21
HUE069214T2 (hu) 2025-02-28
ES2989715T3 (es) 2024-11-27
KR102468436B1 (ko) 2022-11-17
EP2552955A2 (en) 2013-02-06
TWI667346B (zh) 2019-08-01
EP4501956A3 (en) 2025-11-26
BR112012024710A8 (pt) 2021-06-08
HRP20171080T1 (hr) 2017-10-06
ES2633597T3 (es) 2017-09-22
JP2013528354A (ja) 2013-07-11
PT3181581T (pt) 2024-11-21
KR101974794B1 (ko) 2019-05-02
CN102918057A (zh) 2013-02-06
EP4501956A2 (en) 2025-02-05
RU2745989C9 (ru) 2021-09-10
JP6850317B2 (ja) 2021-03-31
HUE069966T2 (hu) 2025-04-28
EP3181581B1 (en) 2024-09-25

Similar Documents

Publication Publication Date Title
PT2552955T (pt) Anticorpos com afinidade modificada para fcrn que promovem a depuração de antigénios
FR23C1023I2 (fr) Anticorps anti-il-36r
CY2019040I1 (el) Aνti-il-23 αντισωματα
HRP20190047T1 (hr) Protutijela koja se vežu na csf1r
BR112013013043A2 (pt) proteínas de repetição concebidas que se ligam á albumina sérica
DK2975051T3 (da) Let-at-isolere bispecifikke antistoffer med nativt immunoglobulinformat
BRPI0919545A2 (pt) anticorpos que se ligam a il-18 e métodos de purificar os mesmos
BRPI0916973A2 (pt) anticorpos para ccr2
BRPI1014262A2 (pt) anticorpos específicos para caderina-17
BR112013017951A2 (pt) moléculas de anticorpo que ligam il-17a e il-17f
PT3409287T (pt) Conjugados anticorpo fármaco (adc) que se ligam a proteínas 191p4d12
CO7010784A2 (es) Moléculas que son anticuerpos con especificidad por ox40 humano
HUE056313T2 (hu) Anti-DLL3 antitest
BR112013016235A2 (pt) anticorpo modificado com meia-vida aumentada
EP3375462C0 (en) Improvements to immobilised biological entities
BR112012030311A2 (pt) anticorpo
DK4459282T3 (da) Monoklonalt interleukin-31-antistof
CO7020875A2 (es) Anticuerpos humanizados que reconocen la alfa-sinucleina
EP2703486A4 (en) ANTI-B7-H3 ANTIBODY
DK3351255T3 (da) Modificerede anti-cd4-antistoffer
SMT201700083B (it) Anticorpi monoclonali
CO6791565A2 (es) Anticuerpos anti-notch1
EP2700447A4 (en) SILICONE OXIDE FILLED CATALYST
DK3202789T3 (da) Anti-vla-4-antistoffer
FI20105715A0 (fi) Asetyloituun HMGB1:een sitoutuva polyklonaalinen vasta-aine